argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
Brixton Metals Announces Upsize of Previously Announced Non-Brokered Private Placement to $8 Million and Closing of Second Tranche
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
